
Ralph I Horwitz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2981191/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Biosocial Pathogenesis. Psychotherapy and Psychosomatics, 2022, 91, 73-77.	4.0	15
2	Population health science as a unifying foundation for translational clinical and public health research. SSM - Population Health, 2022, 18, 101047.	1.3	3
3	Long COVID and Medicine's Two Cultures. American Journal of Medicine, 2022, 135, 945-949.	0.6	7
4	Biology and Lived Experience in Health and Disease: A Tribute to Bruce McEwen (1938–2020), a Scientist without Silos. Psychotherapy and Psychosomatics, 2021, 90, 5-10.	4.0	4
5	Clinimetric Criteria for Patient-Reported Outcome Measures. Psychotherapy and Psychosomatics, 2021, 90, 222-232.	4.0	84
6	COVID-19 and the Future of Clinical Epidemiology. Journal of Clinical Epidemiology, 2021, 138, 189-193.	2.4	2
7	Biosocial medicine: Biology, biography, and the tailored care of the patient. SSM - Population Health, 2021, 15, 100863.	1.3	6
8	Rethinking Table 1. Journal of Clinical Epidemiology, 2021, , .	2.4	3
9	Limited Usefulness of Meta-Analysis for Informing Patient Care. Psychotherapy and Psychosomatics, 2019, 88, 257-262.	4.0	20
10	The Biological and Biographical Basis of Precision Medicine. Psychotherapy and Psychosomatics, 2019, 88, 333-340.	4.0	20
11	An Error in An Old Paper Illustrates the Need for Data/Code Archives - Author response. Journal of Clinical Epidemiology, 2019, 107, 129.	2.4	0
12	Biology, biography, and the translational gap. Science Translational Medicine, 2019, 11, .	5.8	7
13	Randomized trials and evidence in medicine: A commentary on Deaton and Cartwright. Social Science and Medicine, 2018, 210, 32-36.	1.8	10
14	Social Determinants of Treatment Response. American Journal of Medicine, 2018, 131, 480-483.	0.6	8
15	Medicine based evidence and personalized care of patients. European Journal of Clinical Investigation, 2018, 48, e12945.	1.7	13
16	Introduction. What works? And for whom?. Social Science and Medicine, 2018, 210, 22-25.	1.8	6
17	The Use of 5-Alpha Reductase Inhibitors to Manage Benign Prostatic Hyperplasia and the Risk of All-cause Mortality. Urology, 2018, 119, 70-78.	0.5	6
18	Biology, Social Environment, and Personalized Medicine. Psychotherapy and Psychosomatics, 2017, 86, 5-10.	4.0	29

RALPH I HORWITZ

#	Article	IF	CITATIONS
19	Why evidence-based medicine failed in patient care and medicine-based evidence will succeed. Journal of Clinical Epidemiology, 2017, 84, 14-17.	2.4	29
20	A Reply to Stiefel et al. "Losing the â€~Person' in Personalized Medicine― Psychotherapy and Psychosomatics, 2017, 86, 301-301.	4.0	0
21	From Evidence Based Medicine to Medicine Based Evidence. American Journal of Medicine, 2017, 130, 1246-1250.	0.6	72
22	Medicine Based Evidence for Individualized Decision Making: Case Study of Systemic Lupus Erythematosus. American Journal of Medicine, 2017, 130, 1290-1297.e6.	0.6	11
23	5-Alpha Reductase Inhibitors and the Risk of Prostate Cancer Mortality in Men Treated for Benign Prostatic Hyperplasia. Mayo Clinic Proceedings, 2016, 91, 1717-1726.	1.4	11
24	Equity in Cancer Care and Outcomes of Treatment. JAMA - Journal of the American Medical Association, 2016, 315, 1231.	3.8	16
25	Beyond randomised versus observational studies. Lancet, The, 2004, 363, 1660-1661.	6.3	125
26	Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs. New England Journal of Medicine, 2000, 342, 1887-1892.	13.9	3,018
27	Phenylpropanolamine and the Risk of Hemorrhagic Stroke. New England Journal of Medicine, 2000, 343, 1826-1832.	13.9	667
28	Problems in the "Evidence―of "Evidence-Based Medicine― American Journal of Medicine, 1997, 103, 529-535.	0.6	569
29	Can treatment that is helpful on average be harmful to some patients? A study of the conflicting information needs of clinical inquiry and drug regulation. Journal of Clinical Epidemiology, 1996, 49, 395-400.	2.4	107